Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds